A Director at VolitionRX (VNRX) is Buying Shares


Today, a Director at VolitionRX (VNRX), Martin Charles Faulkes, bought shares of VNRX for $197K.

Following this transaction Martin Charles Faulkes’ holding in the company was increased by 2.69% to a total of $7.29 million. Following Martin Charles Faulkes’ last VNRX Buy transaction on June 13, 2019, the stock climbed by 0.8%.

See today’s analyst top recommended stocks >>

Currently, VolitionRX has an average volume of .

Starting in November 2018, VNRX received 12 Buy ratings in a row.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VolitionRX Ltd. is a multi-national life sciences company. It engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Singapore.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts